Arch Therapeutics, Inc. (ARTH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arch Therapeutics, Inc. (ARTH) trades at $0.00 with AI Score 61/100 (Grade B+). Arch Therapeutics, Inc. is a biotechnology company focused on developing and marketing products based on its AC5 self-assembling technology platform. Market cap: 444, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for ARTH: ARTH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ARTH against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ARTH: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
Arch Therapeutics, Inc. (ARTH) Healthcare & Pipeline Overview
Arch Therapeutics, Inc. is a biotechnology firm developing and marketing its AC5 self-assembling technology for advanced wound care. With a focus on hemostasis and leak control, the company targets surgical, trauma, and chronic wound applications. The company operates in the competitive biotechnology landscape, facing challenges typical of early-stage companies.
What Is the Investment Thesis for ARTH?
Arch Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's AC5 technology platform addresses a significant need in wound care, offering potential advantages in hemostasis and leak control. However, the company's negative profit margin of -9221.4% and negative gross margin of -3.2% highlight its current financial challenges. The company's high beta of 4.03 suggests significant volatility relative to the broader market. Successful commercialization of AC5 products and expansion into new markets are key value drivers. Investors should carefully consider the company's financial position, regulatory risks, and competitive landscape before investing. The company's small size and OTC listing add further complexity to the investment decision.
Based on FMP financials and quantitative analysis
ARTH Key Highlights
- Market capitalization of $0.00B reflects the company's early stage and limited revenue generation.
- Negative profit margin of -9221.4% indicates significant losses and the need for substantial revenue growth.
- Negative gross margin of -3.2% suggests challenges in product pricing and cost management.
- Beta of 4.03 indicates high volatility compared to the overall market.
- The company's focus on the AC5 self-assembling technology platform offers potential for innovation in wound care.
Who Are ARTH's Competitors?
ARTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | 3B | 68 |
| CELU Celularity Inc. | $0.73 | +0.44% | $17.56M | 68 |
| PRVB Provention Bio, Inc. | $24.98 | +0.00% | $2.38B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ARTH's Key Strengths?
- Proprietary AC5 self-assembling technology.
- Potential for innovative wound care solutions.
- Focus on unmet needs in hemostasis and leak control.
- Targeted product offerings for surgical and chronic wounds.
What Are ARTH's Weaknesses?
- Limited financial resources and small company size.
- Negative profit and gross margins.
- Dependence on successful commercialization of AC5 products.
- OTC market listing indicating higher risk.
What Could Drive ARTH Stock Higher?
- Potential FDA approval of AC5 Advanced Wound System for specific indications.
- Clinical trials evaluating the efficacy of AC5 technology in various wound care applications.
- Expansion of distribution network to reach new markets.
- Announcement of strategic partnerships or licensing agreements.
- Publication of positive clinical data supporting the benefits of AC5 technology.
What Are the Key Risks for ARTH?
- Regulatory delays or rejection of AC5 products by the FDA.
- Competition from established wound care companies with greater resources.
- Limited financial resources and dependence on raising additional capital.
- Product liability claims related to the use of AC5 technology.
- OTC market listing indicating higher risk and volatility.
What Are the Growth Opportunities for ARTH?
- Expansion into Surgical Markets: Arch Therapeutics has the opportunity to expand the application of its AC5 technology into various surgical specialties. The global surgical hemostats market is projected to reach $4.5 billion by 2028, driven by the increasing volume of surgical procedures and the demand for effective hemostatic agents. Successful adoption of AC5 in surgical settings could significantly increase revenue. The timeline for this growth opportunity depends on regulatory approvals and market acceptance by surgeons.
- Development of Advanced Wound Dressings: The company can leverage its AC5 technology to develop advanced wound dressings for chronic wounds, such as diabetic ulcers and pressure sores. The advanced wound care market is estimated at $10 billion globally, with a growing demand for products that promote faster healing and reduce infection rates. This opportunity requires further research and development to optimize AC5 for wound dressing applications, with a potential timeline of 3-5 years for commercialization.
- Partnerships and Licensing Agreements: Arch Therapeutics can pursue strategic partnerships and licensing agreements with larger healthcare companies to accelerate the commercialization of its AC5 technology. Collaborations can provide access to established distribution channels, marketing expertise, and financial resources. This approach can reduce the company's financial burden and accelerate market penetration. The timeline for securing partnerships depends on the company's ability to demonstrate the value proposition of its technology.
- Geographic Expansion: The company has the potential to expand its market presence beyond the United States into international markets. The global wound care market is diverse, with varying regulatory requirements and market dynamics. Entering new geographic regions requires careful planning and execution, including securing regulatory approvals and establishing distribution networks. The timeline for geographic expansion depends on the specific market and the company's resources.
- Development of Combination Products: Arch Therapeutics can explore the development of combination products that integrate AC5 technology with other therapeutic agents or medical devices. This approach can enhance the efficacy of wound care treatments and address multiple aspects of the healing process. For example, combining AC5 with antimicrobial agents or growth factors could improve wound infection control and tissue regeneration. The timeline for developing combination products depends on the complexity of the formulation and regulatory requirements.
What Opportunities Does ARTH Have?
- Expansion into surgical markets.
- Development of advanced wound dressings.
- Partnerships and licensing agreements.
- Geographic expansion into international markets.
What Threats Does ARTH Face?
- Competition from established wound care companies.
- Regulatory hurdles and clinical trial risks.
- Potential for product liability claims.
- Market acceptance of AC5 technology.
What Are ARTH's Competitive Advantages?
- Proprietary AC5 self-assembling technology platform.
- Patents protecting its wound care products.
- Potential for strong brand recognition in the wound care market.
- First-mover advantage in specific applications of AC5 technology.
What Does ARTH Do?
Founded in 2006 and based in Framingham, Massachusetts, Arch Therapeutics, Inc. is a biotechnology company dedicated to developing and commercializing innovative solutions for wound care. The company's core technology is the AC5 self-assembling peptide platform, designed to promote hemostasis and control fluid leaks in various clinical settings. Arch Therapeutics' flagship products include the AC5 Advanced Wound System and AC5 Topical Hemostat, both intended for topical application to manage bleeding and promote wound healing. These products are targeted for use in surgical procedures, trauma incidents, and the treatment of chronic wounds. The company's focus is on addressing unmet needs in wound management, offering potential benefits in terms of reduced bleeding, improved healing times, and enhanced patient outcomes. As a relatively small company with 8 employees, Arch Therapeutics is navigating the challenges of the biotechnology industry, including regulatory hurdles, clinical trials, and commercialization efforts. The company's success hinges on the continued development and adoption of its AC5 technology in the broader healthcare market.
What Products and Services Does ARTH Offer?
- Develops and markets products based on its AC5 self-assembling technology platform.
- Creates solutions to stop bleeding and control leaking.
- Manages wounds during surgery.
- Provides products for trauma care.
- Offers solutions for interventional care.
- Addresses wound management related to disease.
- Provides AC5 advanced wound system for skin applications.
- Offers AC5 topical hemostat for acute surgical wounds.
How Does ARTH Make Money?
- Develops and patents its AC5 self-assembling technology.
- Manufactures and markets AC5-based products.
- Generates revenue through direct sales of wound care products.
- Potentially licenses its technology to other healthcare companies.
What Industry Does ARTH Operate In?
Arch Therapeutics operates within the competitive biotechnology industry, specifically targeting the wound care market. This market is characterized by ongoing innovation, driven by the need for advanced solutions to address chronic wounds, surgical bleeding, and trauma-related injuries. Key trends include the development of biocompatible materials, advanced hemostatic agents, and regenerative medicine approaches. The company faces competition from established players and emerging companies developing similar technologies. The overall wound care market is expected to grow, driven by factors such as the aging population, rising incidence of diabetes, and increasing demand for advanced wound care products.
Who Are ARTH's Key Customers?
- Hospitals and surgical centers.
- Trauma centers and emergency rooms.
- Wound care clinics.
- Physicians and surgeons.
ARTH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying could signal confidence in ARTH's future prospects, suggesting those closest to the company see value.
- The social trading community seems optimistic about ARTH's potential applications in wound care, fueling positive sentiment.
- Perception of ARTH as an innovator in the medical device space may attract further investment and partnerships.
- Bullish community members highlight the potential market size for ARTH's products, indicating significant growth opportunities.
Bear Case
- Limited news flow around ARTH in the last 30 days might indicate a lack of significant progress or upcoming catalysts.
- Bearish community members express concern about the time it's taking for ARTH to achieve commercial success.
- Market perception of small-cap biotech companies can be volatile, leading to unpredictable stock movements.
- The wound care market is competitive, and ARTH faces established players, which could hinder market penetration.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ARTH Latest News
-
USA Rare Earth Hits Speed Bump As It Unlocks $1.6 Billion In U.S. Funding
Investor's Business Daily · Jun 3, 2026
-
China Rare Earth Firms Rally After Strong Earnings, Beijing Plan
Bloomberg · Apr 29, 2026
-
The Rare Earth Trap: How China Outmaneuvered the Entire Western Defense Industry
Yahoo Finance · Apr 15, 2026
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
ARTH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARTH.
Price Targets
Wall Street price target analysis for ARTH.
ARTH MoonshotScore
What does this score mean?
The MoonshotScore rates ARTH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
USA Rare Earth Hits Speed Bump As It Unlocks $1.6 Billion In U.S. Funding
China Rare Earth Firms Rally After Strong Earnings, Beijing Plan
The Rare Earth Trap: How China Outmaneuvered the Entire Western Defense Industry
Stocks That Hit 52-Week Highs On Tuesday
Leadership: Terrence W. Norchi
CEO
Terrence W. Norchi serves as the CEO of Arch Therapeutics, Inc. His background includes leadership roles in various biotechnology and healthcare companies. He has experience in strategic planning, product development, and commercialization. His expertise spans across multiple therapeutic areas, including wound care and hemostasis. He is responsible for guiding the company's overall strategy and operations, managing a team of 8 employees.
Track Record: Under Terrence W. Norchi's leadership, Arch Therapeutics has focused on developing and marketing products based on its AC5 self-assembling technology platform. Key milestones include advancing the AC5 Advanced Wound System and AC5 Topical Hemostat. His leadership is crucial for navigating regulatory approvals and securing partnerships to drive growth.
ARTH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Arch Therapeutics may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significantly higher risks due to the lack of regulatory oversight and potential for limited liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and potential for lack of transparency.
- Higher risk of fraud or manipulation due to less regulatory oversight.
- Limited liquidity and wider bid-ask spreads.
- Potential for delisting or suspension of trading.
- Greater price volatility compared to stocks listed on major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's patents and intellectual property.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Development of proprietary AC5 self-assembling technology.
- Focus on addressing unmet needs in wound care.
- Management team with experience in biotechnology.
- Patents protecting its wound care products.
- Ongoing efforts to commercialize AC5 products.
What Investors Ask About Arch Therapeutics, Inc. (ARTH) — Healthcare
What does Arch Therapeutics, Inc. do?
Arch Therapeutics, Inc. is a biotechnology company that develops and markets products based on its proprietary AC5 self-assembling technology platform. The company's focus is on creating innovative solutions for wound care, specifically to stop bleeding and control leaking in surgical, trauma, and chronic wound settings. Their flagship products, the AC5 Advanced Wound System and AC5 Topical Hemostat, are designed for topical application to manage bleeding and promote wound healing. The company aims to address unmet needs in the wound care market by offering advanced solutions that improve patient outcomes.
What do analysts say about ARTH stock?
As of March 16, 2026, there is limited analyst coverage available for Arch Therapeutics (ARTH) due to its OTC listing and small market capitalization. Key valuation metrics, such as price-to-earnings (P/E) ratio, are not meaningful due to the company's negative earnings. Growth considerations revolve around the successful commercialization of its AC5 technology and expansion into new markets. Investors should conduct their own thorough research and consider the company's financial position, regulatory risks, and competitive landscape before making any investment decisions. The high beta of 4.03 indicates significant volatility.
What are the main risks for ARTH?
Arch Therapeutics faces several key risks, including regulatory hurdles associated with obtaining FDA approval for its AC5 products. Competition from established wound care companies with greater resources poses a significant challenge. The company's limited financial resources and dependence on raising additional capital create financial risk. Product liability claims related to the use of AC5 technology are a potential concern. The OTC market listing adds further risk due to limited liquidity and potential for price volatility. Investors should carefully consider these risks before investing in ARTH.
How does Arch Therapeutics, Inc. manage patent expiration risks?
As of March 16, 2026, specific details regarding Arch Therapeutics, Inc.'s patent expiration management strategies are not available. However, as a biotechnology company, it is crucial for Arch Therapeutics to actively manage its intellectual property portfolio. This includes continuously innovating and developing new products based on its AC5 technology platform to extend its market exclusivity. Furthermore, the company may seek to obtain additional patents for new applications or formulations of its AC5 technology to protect its competitive advantage. Investors should monitor the company's patent filings and intellectual property strategy to assess its long-term growth potential.
What revenue streams does Arch Therapeutics, Inc. have in healthcare?
Arch Therapeutics, Inc.'s primary revenue stream is currently derived from the sales of its AC5 Advanced Wound System and AC5 Topical Hemostat. These products are targeted for use in surgical procedures, trauma incidents, and the treatment of chronic wounds. The company generates revenue through direct sales to hospitals, surgical centers, wound care clinics, and physicians. As of March 16, 2026, the specific breakdown of revenue by product line, therapeutic area, and geographic market is not publicly available. However, successful expansion into new markets and the development of additional AC5-based products could diversify the company's revenue streams in the future.
What are the key factors to evaluate for ARTH?
Arch Therapeutics, Inc. (ARTH) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does ARTH data refresh on this page?
ARTH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ARTH's recent stock price performance?
Arch Therapeutics, Inc. (ARTH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AC5 self-assembling technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited and less reliable than major exchange data.
- AI analysis is pending and may provide further insights.